D.E. Shaw & Co
SIOX

D.E. Shaw & Co’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

D.E. Shaw & Co’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-23,028
Closed -$8K – 5704
2022
Q2 		$8K Buy
+23,028
New +$9.53K ﹤0.01% 5178
2021
Q2 		– Sell
-165,235
Closed -$431K – 5117
2021
Q1 		$431K Buy
+165,235
New +$467K ﹤0.01% 3570
2020
Q3 		– Sell
-161,702
Closed -$456K – 4278
2020
Q2 		$456K Buy
161,702
+66,859
+70% +$214K ﹤0.01% 3430
2020
Q1 		$231K Buy
94,843
+69,750
+278% +$252K ﹤0.01% 3588
2019
Q4 		$128K Buy
+25,093
New +$139K ﹤0.01% 3859
2018
Q1 		– Sell
-9,047
Closed -$381K – 3857
2017
Q4 		$381K Sell
9,047
-277
-3% -$12.4K ﹤0.01% 3121
2017
Q3 		$513K Sell
9,324
-201,593
-96% -$34M ﹤0.01% 2892
2017
Q2 		$39.1M Buy
210,917
+19,409
+10% +$3.4M 0.06% 361
2017
Q1 		$22.9M Buy
191,508
+866
+0.5% +$90.8K 0.04% 516
2016
Q4 		$18.9M Sell
190,642
-2,069
-1% -$218K 0.03% 649
2016
Q3 		$21.6M Buy
192,711
+975
+0.5% +$117K 0.04% 544
2016
Q2 		$19.7M Buy
191,736
+2,797
+1% +$280K 0.04% 554
2016
Q1 		$17.4M Sell
188,939
-12,323
-6% -$1.31M 0.03% 598
2015
Q4 		$29M Sell
201,262
-44,288
-18% -$5.76M 0.04% 480
2015
Q3 		$25.4M Buy
245,550
+26,800
+12% +$3.14M 0.04% 530
2015
Q2 		$35.7M Buy
+218,750
New +$37.1M 0.05% 423

Other funds holding SIOX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TVWM
Tower View Wealth Management Shorewood, Wisconsin $227M AUM 41.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PCA
Private Capital Advisors Darien, Connecticut $1.14B AUM 48.66% 1-Year Est. Return
CIA
Cladis Investment Advisory Billings, Montana $182M AUM 33.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

D.E. Shaw & Co's SIOX Position: Q3 2022 in Review

D.E. Shaw & Co sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q3 2022, closing a stake of 23,028 shares — an estimated $8K sold.

D.E. Shaw & Co first reported a position in SIOX in Q2 2015 and held it in 16 quarters. The position peaked at $39.1M in Q2 2017. 40 funds tracked by Wall St. Rank hold SIOX as of Q3 2022.

  • D.E. Shaw & Co reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • D.E. Shaw & Co sold 23,028 Sio Gene Therapies Inc. Common Stock shares in Q3 2022, an estimated $8K.
  • D.E. Shaw & Co first reported a position in Sio Gene Therapies Inc. Common Stock in Q2 2015 and held it in 16 quarters.
  • D.E. Shaw & Co's Sio Gene Therapies Inc. Common Stock position peaked at $39.1M in Q2 2017.
  • 40 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q3 2022.

Based on D.E. Shaw & Co's 13F filing for Q3 2022, filed 14 Nov 2022.